Thrive I: Efficacy and Tolerability of the Novel, Oral Direct Thrombin Inhibitor Ximelagatran Compared with Standard Therapy for the Treatment of Acute Deep Venous Thrombosis

Reviewer: Walter F. Sall, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 10 de diciembre del 2001

Share article


English

Presenter: Sam Schulman
Presenter's Affiliation: Karolinska Hospital, Stockholm, Sweden
Type of Session: Scientific

Background

  • Ximelagatran is an orally available, direct thrombin inhibitor. It is absorbed and converted to its active form, melagatran. It has a rapid onset, reaching peak serum concentration after 2-3 hours and does not require dose titration or routine coagulation monitoring. No drug or food interactions are known.
  • The objective of this study was to determine the safety, efficacy and optimal dosing for this drug in comparison to standard dalteparin followed by coumadin for patients with documented DVT.

    Materials and Methods

  • This was a randomized, controlled, dose-blinded study from 41 centers in Europe. Four dose levels of Ximelegatran (from 24 to 60 mg twice daily) vs. Dalteparin (20 mg/kg) plus warfarin were tested.
  • Outcome measures included change in thrombus size and Marder score as assessed by venography on the day of randomization and on day 14. Symptomatic progression was also assessed.
  • 350 patients were evaluated. 4% of patients had cancer.
  • Up to 24 hours of treatment with conventional anti-coagulation was allowed prior to randomization.

    Results

  • 69% of patients had regression of thrombus. The change was similar among all dose levels and the dalteparin group.
  • No difference in the change in Marder Score was seen in any of the groups.
  • A similar improvement in pain symptoms was seen in all groups.
  • The PE rate was 1-2% in all groups. 1-2% discontinued therapy due to bleeding complications in all groups.

    Author's Conclusions

  • Ximelegatran is a well tolerated and efficacious alternative to standard dalteparin/coumadin in the treatment of DVT.
  • Routine monitoring of seum drug levels or coagulation is not necessary.
  • Initial parenteral treatment with heparin or low molecular weight heparin is unneccessary.
  • Comparable effect of different dose levels of the drug suggest a wide range of therapeutic efficacy

    Clinical/Scientific Implications
    Oral ximelegatran appears to be a satisfactory alternative to conventional parenteral anticoagulant therapy in the initial treatment of DVT. Its oral formulation promises to improve patient compliance and simplify treatment.

    Oncolink's ASH Coverage made possible by an unrestricted Educational Grant from Amgen.

    English
    News
    Novel Agent Tolerable, Active for Advanced Colorectal Cancer

    Aug 29, 2012 - For patients with previously treated metastatic colorectal cancer who are refractory or intolerant to standard therapies, treatment with a novel oral nucleoside antitumor agent, TAS-102, is tolerable and shows promising efficacy, according to a phase 2 study published online Aug. 28 in The Lancet Oncology.



  • I Wish You Knew

    How cancer patients have changed my life

    View More



    Blogs and Web Chats

    OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




    OncoLink OncoPilot

    Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

    Más información